Drugs / ITIL-168
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05393635 | Aug → Dec 2022 | cervical cancer, head and neck squamous cell carcinoma, non-small cell lung carcinoma | Instil Bio | Withdrawn | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT05050006 | Oct 2021 → Feb 2023 | cutaneous melanoma | Instil Bio | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2021-09-13 | Instil Bio | Regulatory Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma instilbio.com ↗ |
| 2021-04-27 | Instil Bio | Regulatory Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma instilbio.com ↗
Instil Bio, Inc. (“Instil”) (Nasdaq: TIL) received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of melanoma stages IIB to IV with its ITIL-168 TIL therapy. |
| 2021-04-12 | Instil Bio | Results Instil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking e-Poster at the 2021 American Association for Cancer Research (AACR) Annual Meeting instilbio.com ↗
In this compassionate use setting in which patients had exhausted all other available therapies, a one-time treatment with TILs was able to induce a remission in more than half of the treated patients. |
All press releases naming this drug 3 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ITIL-168 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05393635 ↗ |
| Modality | Cell therapy | “ITIL-168 is a cell therapy product derived from a patient's own TILs.” NCT05050006 ↗ |